Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.

Abstract

The results suggest that posttherapy PSA declines can be used as a surrogate end point to evaluate new agents in hormone-refractory prostate cancer. The criteria for response need prospective validation in phase III trials.